With approximately $450 million in facility-specific investment and approximately 150 permanent operating jobs announced, this project clears both of AFT's qualifying thresholds ($100 million in facility-specific investment OR 100 permanent operating jobs). It is also confirmed by official public sources and involves a physical manufacturing facility in the United States.
View full methodology →The pharmaceuticals context.
Pharmaceutical manufacturers are committing billions to new U.S. production capacity for active ingredients, injectable medicines, biologics and other high-demand treatments. North Carolina and Indiana remain major centers of investment, while new facilities are being planned across the South. The current project pipeline includes both large greenfield campuses and major expansions of established production sites.
At a glance
- Company
- Roche Group (Genentech)
- Industry
- Pharmaceuticals
- Location
- Oceanside, California
- Investment
- Approximately $450.0M
- Permanent jobs announced
- Approximately 150
- Status
- Operational
- Announced
- Feb 10, 2023
- Operations began
- Date not publicly specified
- Added to tracker
- Sep 1, 2026
Official references
- Genentech's February 10, 2023 Oceanside commercial-biologics facility groundbreaking announcement https://www.gene.com/media/statements/ps_020923
- Genentech Oceanside campus manufacturing profile https://www.gene.com/contact-us/visit-us/oceanside
- Genentech Oceanside project one-pager https://www.gene.com/assets/frontend/pdf/content/media/news-features/Genentech_Oceanside_One-Pager.pdf
Cite this project
American Factory Tracker. "Oceanside Next-Generation Commercial Biologics Facility — Roche Group, Oceanside, CA." https://americanfactorytracker.com/projects/roche-genentech-oceanside-commercial-biologics-facility. Accessed November 4, 2026.
Please also cite the original sources listed above for underlying figures.